Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic hepatitis C virus (HCV) genotypes 1, 4, 5, or 6 infection Age: Adults Condition: Treatment-naive with or without cirrhosis |
Dose: Tablet – 90 mg of Ledipasvir and 400 mg of Sofosbuvir Frequency: once daily Duration: 12 weeks Note: Hepatic impairment (mild, moderate, or severe): No dosage adjustment required. |
|
Indication: Chronic hepatitis C virus (HCV) genotypes 1, 4, 5, or 6 infection Age: Adults Condition: Treatment-experienced without cirrhosis |
Dose: Tablet – 90 mg of Ledipasvir and 400 mg of Sofosbuvir Frequency: once daily Duration: 12 weeks Note: Hepatic impairment (mild, moderate, or severe): No dosage adjustment required. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy – not established Note: Safety and efficacy not established |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild or moderate renal impairment |
Dose: Dose: Note: No dosage adjustment required |
|
Condition: Severe renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73 m²) or end stage renal disease |
Dose: Dose: Note: No dosage recommendation can be given |
Administration
- Can take with or without food
- Take at same time daily
Side Effect
- Asthenia (31-36%)
- Fatigue (4-18%)
- Headache (13-29%)
- Cough (5-11%)
- Nausea (6-9%)
- Diarrhea (3-7%)
- Dizziness (1-5%)
- Dyspnea (3-9%)
- Insomnia (3-6%)
- Increased bilirubin More than 1.5 x ULN (Less than 1 to 3%)
- Increased lipase More than 3 x ULN (Less than 1 to 3%)
- Myalgia (4-9%)
- Irritability (7-8%)
- Asymptomatic creatine kinase elevation
- Grades 3/4
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Rifampicin, St. John's wort, carbamazepine, phenytoin, modafinil, phenobarbital/oxcarbazepine, rifabutin/rifapentine
|
Reduced therapeutic effect
|
|
P-gp and/or BCRP inhibitors
|
Interaction mentioned but specific effect not detailed
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep out of the reach of children. Keep in a cool & dry place. Protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.